Beginning June 1, 2015, the vast majority drugs in China, except for narcotic and Type 1 psychotropic drugs, will be free from government-set pricing.

NDRC has announced that it is investigating costs and prices charged by 60 foreign and domestic drug makers in China.

The new interpretation focuses on issues such as intentionally purchasing counterfeit products and online shopping.

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Measures for the Protection of Drug Trial Data...

Following the reform of the drug and device approval system by China's State Council in August, the China Food and Drug Administration ("CFDA") has finally unveiled its implementation policies regarding improvements to the drug approval system ..

On April 20, 2019, the Chinese government submitted a second draft of the Drug Administration Law of the People's Republic of China to the Standing Committee of the NPC for deliberation.

On September 7, China's Ministry of Commerce, the National Health Commission, and the National Medical Products Administration issued a notice announcing the expansion of pilot programs for foreign investment...

China has recently seen the first decision in a case initiated under its patent linkage system. Under this system, when a generic drug company files an application...

NMPA and CNIPA Jointly Issued Implementation Measures for the Early Resolution Mechanism for Drug Patent Disputes (Trial) (Patent Linkage)...

CN patent linkage measures finalized and issued by NMPA.

We are writing and editing the current issue of gossIP "working from home". The city of Shanghai is facing a big flare-up of Covid19 cases and therefore it is implementing a very strict lockdown.

The new issue of GossIP reports some IP, Tech and Food cases which are on the top list of this beginning 2021.

The newly revised Patent Law launches protection term compensation system for invention patent which stipulates protection term adjustment for loss of term caused by patent examination and, laying particular emphasis on ...

近日，辉瑞的paxlovid将投放北京社区医院的消息在网上引起了不小的讨论。其实，paxlovid并非完全的新药，也不是最近才突然出现。它实际上是奈玛特&

国務院新聞弁公...

2020년 6월 28일, 중국 제약산업협회(医药物资协会)는 ‘2019년 중국 제약 지식재산권 산업 발전 현황 보고(2019年度中国医药知识产权行业发展状况报告)'를 발표함

As the direct impact of COVID-19 in China gradually subsides, the government has released the 2020 legislation plans and the working report for the first quarter of 2020.

Anti-corruption has remained an area of focus area for Chinese authorities in the first half of 2025, with major legislative updates and enforcement cases.

The China Food and Drug Administration ("CFDA") recently announced several draft rules, most notably, the Draft Amendment of the Provisions for Drug Registration (also known as the Drug Registration Rules, DRR) and the Draft Administrative Regulations on the Review and Approval of Drug Contract Manufacturing ("Draft Contract Manufacturing Rules), which will significant impact the pharmaceutical industry. The CFDA is soliciting public comments on both Rules through early December, 2013.

The China Food and Drug Administration ("CFDA") recently proposed a draft circular to address the priority review designation issue for medical devices, namely the Circular Regarding Soliciting Comments Regarding Priority Review Designation Procedure for Medical Devices (CFDA Circular [2016] No.40, the "Circular").